Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner
Expressed predominantly in liver. Also present in plasma
Expressed in plasma (at protein level) (PubMed:32827448). Expressed in liver (PubMed:32827448)
The N-terminal acidic repeat region mediates, in part, the glycosaminoglycan-accelerated thrombin inhibition
A hemostatic disorder characterized by a tendency to recurrent thrombosis.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to SERPIND1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 1
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03203421 | Malaria | A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2 | PHASE1, PHASE2 | COMPLETED |